Fierce Biotech July 17, 2024
A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and didn’t hint at any plans to pause this work to conserve cash.
Now, with the biotech eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce.
That 12% equates to 21 employees, the biotech explained in a July 16 Securities and Exchange Commission filing, who will all have left the company by the end of September. Combined with “cost containment measures,” these layoffs are expected to extend Caribou’s runway of $311.8...
Today's Sponsors
Today's Sponsor